Recent studies have demonstrated that disruption of TGF-β signaling by introduction of a dominant negative TβRII in the prostate epithelium of a preclinical adenocarcinoma mouse model leads to accelerated tumor growth (Pu et al., 2017). The gene discussed is TGFB1; the disease is neoplasm.